Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
Information source: Pfizer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obesity
Intervention: CP-742,033 (Drug); Fenofibrate (Drug)
Phase: Phase 1
Status: Withdrawn
Sponsored by: Pfizer Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
The purpose of this study is to determine whether fenofibrate effects the toleration, safety,
or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
Clinical Details
Official title: A Phase 1, Randomized, Investigator and Subject Blind, Sponsor Open Study to Determine the Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033 When Co-Administered in Otherwise Healthy Obese Adult Subjects
Study design: Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Toleration and safety
Secondary outcome: Efficacy biomarkers, serum lipids
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- BMI of 30-40 kg/m2
Exclusion Criteria:
- Women of childbearing potential
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: November 2006
Last updated: December 11, 2006
|
